---
figid: PMC3928074__nihms550827f1
figtitle: Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic
  Lymphocytic Leukemia (CLL)
organisms:
- NA
pmcid: PMC3928074
filename: nihms550827f1.jpg
figlink: /pmc/articles/PMC3928074/figure/F1/
number: F1
caption: Figure shows scheme of VEGF receptor signaling pathway in CLL as well as
  aspects of pathway targeted by bevacizumab, AZD2171, and sunitinib malate.
papertitle: Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic
  Lymphocytic Leukemia (CLL).
reftext: Tait Shanafelt, et al. Leuk Lymphoma. ;51(12):2222-2229.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9557571
figid_alias: PMC3928074__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Danio rerio
redirect_from: /figures/PMC3928074__F1
ndex: 487e74c0-dee7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3928074__nihms550827f1.html
  '@type': Dataset
  description: Figure shows scheme of VEGF receptor signaling pathway in CLL as well
    as aspects of pathway targeted by bevacizumab, AZD2171, and sunitinib malate.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - STAT3
  - SETD2
  - ARNT
  - MIA3
  - MCL1
  - XIAP
  - BCL2L1
  - MYC
  - EP300
  - kita
  - ngfra
  - vegfaa
  - stat3
  - arnt
  - arnt2
  - xiap
  - myca
  - AZD2171
  - Ser
---
